Typical and atypical antipsychotics differentially affect long-term incidence rates of the metabolic syndrome in first-episode patients with schizophrenia: a retrospective chart review.

No abstract is available for this paper.

• Publication year

  2008

• Venue

  Schizophrenia Research

• Publication date

  2008-04-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1016/j.schres.2008.01.028PMID 18299188
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) Detection, Evaluation, and Treatment of High Blood Cholesterol Education Program (NCEP) Expert Panel on Executive Summary of the Third Report of the National

  2009cited by this paper
• Metabolic syndrome and insulin resistance in schizophrenia patients receiving antipsychotics genotyped for the methylenetetrahydrofolate reductase (MTHFR) 677C/T and 1298A/C variants.

  2008cited by this paper
• Mortality in schizophrenia and schizoaffective disorder: an Olmsted County, Minnesota cohort: 1950-2005.

  2008cited by this paper
• Concordance of standard and modified NCEP ATP III criteria for identification of metabolic syndrome in outpatients with schizophrenia treated with antipsychotics: a corollary from the CLAMORS study.

  2008cited by this paper
• Weight gain induced by haloperidol, risperidone and olanzapine after 1 year: findings of a randomized clinical trial in a drug-naïve population.

  2008cited by this paper
• Major changes in glucose metabolism, including new-onset diabetes, within 3 months after initiation of or switch to atypical antipsychotic medication in patients with schizophrenia and schizoaffective disorder.

  2008cited by this paper
• Metabolic syndrome in outpatients receiving antipsychotic therapy in routine clinical practice: A cross-sectional assessment of a primary health care database

  2008cited by this paper
• The obesity epidemic in the United States--gender, age, socioeconomic, racial/ethnic, and geographic characteristics: a systematic review and meta-regression analysis.

  2007cited by this paper
• Impaired glucose tolerance in first‐episode drug‐naïve patients with schizophrenia

  2007cited by this paper
• Cardiovascular and metabolic risk in outpatients with schizophrenia treated with antipsychotics: results of the CLAMORS Study.

  2007cited by this paper
• Metabolic syndrome and mental illness.

  2007cited by this paper
• Weight gain, dyslipidemia and altered parameters for metabolic syndrome on first episode psychotic patients after six-month follow-up.

  2007cited by this paper
• Antipsychotic medications: metabolic and cardiovascular risk.

  2007cited by this paper
• Metabolic syndrome in Thai schizophrenic patients: a naturalistic one-year follow-up study

  2007cited by this paper
• Incidence of new onset metabolic syndrome with atypical antipsychotics in first episode schizophrenia: a six-week prospective study in Indian female patients.

  2007cited by this paper
• Metabolic side effects of antipsychotic medication

  2007cited by this paper
• Comparison of metabolic syndrome incidence among schizophrenia patients treated with aripiprazole versus olanzapine or placebo.

  2007cited by this paper
• Abnormal glucose metabolism in patients treated with antipsychotics.

  2007cited by this paper
• Planning for the optimal design of studies to personalize antipsychotic prescriptions in the post-CATIE era: the clinical and pharmacoepidemiological data suggest that pursuing the pharmacogenetics of metabolic syndrome complications (hypertension, diabetes mellitus and hyperlipidemia) may be a reas

  2007cited by this paper
• Clinical Practice and Epidemiology in Mental Health Prevalence of Diabetes, Metabolic Syndrome and Metabolic Abnormalities in Schizophrenia over the Course of the Illness: a Cross-sectional Study

  2006influential reference
• Antipsychotic drugs and diabetes—an application of the Austin Bradford Hill criteria

  2006cited by this paper
• An open-label extension trial of risperidone monotherapy in the treatment of bipolar I disorder

  2006cited by this paper
• Metabolic abnormalities associated with second generation antipsychotics: fact or fiction? Development of guidelines for screening and monitoring.

  2006influential reference
• Metabolic Monitoring for Patients Treated with Antipsychotic Medications

  2006cited by this paper
• Metabolic syndrome and the risk of coronary heart disease in 367 patients treated with second-generation antipsychotic drugs.

  2006cited by this paper
• Prevalence of the metabolic syndrome in patients with schizophrenia treated with antipsychotic medication.

  2006influential reference
• Prevalence of overweight and obesity in the United States, 1999-2004.

  2006cited by this paper
• Body weight and self-esteem in patients with schizophrenia evaluated with B-WISE.

  2006cited by this paper
• The Global Burden of the Metabolic Syndrome and its Consequences for Diabetes and Cardiovascular Disease

  2006cited by this paper
• Screening for diabetes and other metabolic abnormalities in patients with schizophrenia and schizoaffective disorder: evaluation of incidence and screening methods.

  2006cited by this paper
• Schizophrenia and increased risks of cardiovascular disease.

  2005cited by this paper
• Diagnosis and Management of the Metabolic Syndrome: An American Heart Association/National Heart, Lung, and Blood Institute Scientific Statement

  2005cited by this paper
• Diagnosis and management of the metabolic syndrome: an American Heart Association/National Heart, Lung, and Blood Institute Scientific Statement.

  2005cited by this paper
• Metabolic syndrome and schizophrenia.

  2005influential reference
• Challenges in the management of bipolar depression.

  2005cited by this paper
• Belgian consensus on metabolic problems associated with atypical antipsychotics

  2005cited by this paper
• The Clinical Antipsychotic Trials Of Intervention Effectiveness (CATIE) Schizophrenia Trial: clinical comparison of subgroups with and without the metabolic syndrome.

  2005cited by this paper
• The changing face of cardiovascular risk.

  2005cited by this paper
• Prevalence of the metabolic syndrome in patients with schizophrenia: baseline results from the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) schizophrenia trial and comparison with national estimates from NHANES III.

  2005cited by this paper
• Second-Generation (Atypical) Antipsychotics and Metabolic Effects

  2005influential reference
• [Drug-induced diabetes mellitus: the exemple of atypical antipsychotics].

  2005cited by this paper
• Schizophrenia and comorbid metabolic disorders.

  2005cited by this paper
• Schizophrenia, the metabolic syndrome and diabetes

  2004cited by this paper
• Characterizing Coronary Heart Disease Risk in Chronic Schizophrenia: High Prevalence of the Metabolic Syndrome

  2004cited by this paper
• Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study): case-control study.

  2004cited by this paper
• Antipsychotic medications: compliance and attitudes towards treatment

  2004cited by this paper
• Physical health monitoring of patients with schizophrenia.

  2004cited by this paper
• Increasing prevalence of the metabolic syndrome among u.s. Adults.

  2004cited by this paper
• The prevalence of the metabolic syndrome in patients with schizoaffective disorder--bipolar subtype.

  2004cited by this paper
• Obesity as a risk factor for antipsychotic noncompliance.

  2004cited by this paper
• The metabolic syndrome.

  2003cited by this paper
• Impaired fasting glucose tolerance in first-episode, drug-naive patients with schizophrenia.

  2003cited by this paper
• Metabolic syndrome in patients with schizophrenia.

  2003cited by this paper
• Increased visceral fat distribution in drug-naive and drug-free patients with schizophrenia

  2002cited by this paper
• Secular trends in overweight and obesity among Finnish adolescents in 1977–1999

  2002cited by this paper
• Prevalence of the metabolic syndrome among US adults: findings from the third National Health and Nutrition Examination Survey.

  2002cited by this paper
• Medical comorbidity in psychiatric inpatients: relation to clinical outcomes and hospital length of stay.

  2002cited by this paper
• Changes in body mass index for individuals with and without schizophrenia, 1987-1996.

  2002cited by this paper
• Antipsychotic-induced weight gain: a review of the literature.

  2001cited by this paper
• Mental disorders and cause-specific mortality

  2001cited by this paper
• Risk factors for suicide in young people suffering from schizophrenia: a long-term follow-up study.

  2001cited by this paper
• Cardiovascular morbidity and mortality associated with the metabolic syndrome.

  2001cited by this paper
• Causes of the excess mortality of schizophrenia.

  2000cited by this paper
• Time trends in schizophrenia mortality in Stockholm County, Sweden: cohort study

  2000cited by this paper
• Mortality and causes of death in schizophrenia in Stockholm county, Sweden.

  2000cited by this paper
• The association of medical comorbidity in schizophrenia with poor physical and mental health.

  1999cited by this paper
• The distribution of body mass index among individuals with and without schizophrenia.

  1999cited by this paper
• Suicide in young schizophrenic patients during and after inpatient treatment

  1996cited by this paper
• Waist circumference as a measure for indicating need for weight management

  1995cited by this paper
• Summary of the second report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel II)

  1993cited by this paper
• BIOCHEMICAL DISTURBANCES IN MENTAL DISORDERS

  1942cited by this paper
• BIOCHEMICAL DISTURBANCES IN MENTAL DISORDERS: I. ANTI-INSULIN EFFECT OF BLOOD IN CASES OF SCHIZOPHRENIA

  1942cited by this paper
• BLOOD SUGAR STUDIES IN DEMENTIA PRAECOX AND MANIC-DEPRESSIVE INSANITY

  1921cited by this paper

• Research Progress on the Regulation of Schizophrenia-Related Signaling Pathways by LncRNA

  2026cites this paper
• Cardiometabolic monitoring in children and adolescents prescribed antipsychotics in Australian primary care, 2011 to 2017

  2025cites this paper
• The Impact of Metformin on Weight and Waist Circumference in Patients Treated With Clozapine: A One‐Year Retrospective Cohort Study

  2025cites this paper
• Prevalence and predictors of metabolic syndrome among psychiatric patients receiving antipsychotic treatment in Africa: a systematic review and meta-analysis

  2025cites this paper
• Prevalence, Mortality, and Risk Factors of Acute Myocardial Infarction in Patients with Schizophrenia: A Systematic Review and Meta-Analysis

  2025cites this paper
• Comparing cardiorespiratory fitness, body composition, and muscular endurance of patients with schizophrenia and schizoaffective disorders with a population-based sample

  2024cites this paper
• Increased risk of atypical antipsychotics-induced metabolic syndrome associated with MIF CATT >5/6 among females with chronic schizophrenia.

  2024cites this paper
• Retrospective chart review of metabolic screening of patients receiving clozapine and long-acting injectable antipsychotic medications

  2024cites this paper
• Metabolic syndrome in adolescents with mental disorders: diagnostics, prevention and treatment

  2024cites this paper
• Study of factors associated with obesity in patients using antipsychotics in schizophrenia

  2024cites this paper
• Understanding the potential mechanisms of disease modifying effects of physical activity and exercise in people with schizophrenia.

  2024cites this paper
• Long non-coding RNAs in schizophrenia: Genetic variations, treatment markers and potential targeted signaling pathways.

  2023cites this paper
• Pilot and Feasibility Studies of a Lifestyle Modification Program Based on the Health Belief Model to Prevent the Lifestyle-Related Diseases in Patients with Mental Illness

  2023cites this paper
• Metabolic disorders induced by psychotropic drugs.

  2023cites this paper
• Profiles and diagnostic value of intestinal microbiota in schizophrenia patients with metabolic syndrome

  2023cites this paper
• Differing Prevalence and Correlates of Metabolic Syndromes Between Chlorpromazine and Clozapine: A 10-year Retrospective Study of a Male Chinese Cohort

  2022cites this paper
• Halting the Metabolic Complications of Antipsychotic Medication in Patients with a First Episode of Psychosis: How Far Can We Go with the Mediterranean Diet? A Pilot Study

  2022cites this paper
• Metabolic Syndrome And Lifestyle Factors In Patients With Schizophrenia-A Cross Sectional Hospital Based Study

  2022cites this paper
• Recognition and management of clozapine adverse effects: A systematic review and qualitative synthesis

  2022cites this paper
• Diabetes care in the acute psychiatric inpatient setting: A logic model for service delivery.

  2022cites this paper
• Prevalence of metabolic syndrome and related factors in a large sample of antipsychotic naïve patients with first-episode psychosis: Baseline results from the PAFIP cohort.

  2022cites this paper
• Second-Generation Antipsychotics’ Effectiveness and Tolerability: A Review of Real-World Studies in Patients with Schizophrenia and Related Disorders

  2022cites this paper
• Schizophrenia and Related Psychoses

  2021cites this paper
• Prevalence of metabolic syndrome among patients with schizophrenia in Ethiopia

  2021cites this paper
• Metabolic syndrome in antipsychotic-naïve patients with first-episode psychosis: a systematic review and meta-analysis

  2021cites this paper
• The relationship between brain-derived neurotrophic factor and metabolic syndrome in patients with chronic schizophrenia: A systematic review.

  2021cites this paper
• Mind-Body Connection: Cardiovascular Sequelae of Psychiatric Illness.

  2021cites this paper
• Medical Comorbidities in 181 Patients With Bipolar Disorder vs. Schizophrenia and Related Psychotic Disorders: Findings From a Single-Center, Retrospective Study From an Acute Inpatients Psychiatric Unit

  2021cites this paper
• Galectin-3 possible involvement in antipsychotic-induced metabolic changes of schizophrenia: A minireview

  2021cites this paper
• Dietary Habits and Obesity in Patients with Psychotic Disorders in Rural Areas in Northwestern Greece

  2021cites this paper
• Prescribing pattern of antipsychotic medication for first-episode psychosis: a retrospective cohort study

  2021cites this paper
• Prevalence of possible idiopathic normal pressure hydrocephalus in older inpatients with schizophrenia: a replication study

  2020cites this paper
• Sex differences in the association of body mass index with symptoms and cognitive deficits in Chinese patients with chronic schizophrenia

  2020cites this paper
• Metabolic Syndrome and Mental Disorders: A Literature Review

  2020cites this paper
• Safety of Use of Clozapine in Patients With Schizophrenia With Comorbid Diabetes Mellitus

  2020cites this paper
• A study on haloperidol and risperidone induced metabolic derangements in patients with newly diagnosed schizophrenia

  2020cites this paper
• Observed Social Support and Willingness for the Treatment of Patients with Schizophrenia

  2020cites this paper
• Prescription patterns of antipsychotics in the management of first episode psychosis at three psychiatric hospitals in Khartoum, 2018: A descriptive cross-sectional study

  2020cites this paper
• Actitud de los psiquiatras respecto al uso de olanzapina en la práctica clínica: una encuesta nacional

  2020cites this paper
• Mortality Risk Associated with Haloperidol Use Compared with Other Antipsychotics: An 11-Year Population-Based Propensity-Score-Matched Cohort Study

  2020cites this paper
• Observed Social Support and Willingness for the Treatment of Patients with Schizophrenia

  2020cites this paper
• Effects of therapeutic lifestyle change mentoring on cardio-metabolic factors for schizophrenia.

  2020cites this paper
• Metabolic Side Effects of Antipsychotic Medication: An Overview

  2019cites this paper
• Metabolic syndrome among older adults with schizophrenia spectrum disorder: Prevalence and associated factors in a multicenter study.

  2019cites this paper
• Patients with first episode psychosis and chronic schizophrenia may not differ in mean platelet volume affecting its value as an indicator of cardiovascular disease

  2019cites this paper
• High prevalence of metabolic alterations in Latin American patients at initial stages of psychosis

  2019cites this paper
• Depression and Metabolic Syndrome: Two Sides of the Same Coin

  2019cites this paper
• The Novel Perspectives of Adipokines on Brain Health

  2019cites this paper
• Assessment of Long Term Metabolic Effects of Atypical Antipsychotics in Schizophrenia Patients

  2019cites this paper
• Computational Approaches for Identification of Pleiotropic Biomarker Profiles in Psychiatry.

  2019cites this paper
• Risk Factors of Metabolic Syndrome Among Patients Receiving Antipsychotics: A Retrospective Study

  2019cites this paper
• A Retrospective Chart Review of Screening on the Prevalence of Metabolic Syndrome (MetS) in an Irish Community Mental Health Service

  2019cites this paper
• PREVALENCE OF METABOLIC SYNDROME AMONG PATIENTS WITH SCHIZOPHRENIA IN THE CENTER FOR MENTAL HEALTH – “PROLET”, PSYCHIATRIC HOSPITAL -SKOPJE

  2019cites this paper
• Bayesian Meta-analysis of Multiple Continuous Treatments with Individual Participant-Level Data: An Application to Antipsychotic Drugs

  2019cites this paper
• Early Detection of Metabolic Abnormalities in Patients with Newly Diagnosed Schizophrenia on Atypical Antipsychotics

  2019cites this paper
• Şizofreni tanılı hastalarda metabolik sendrom ve D vitamini düzeyleri ilişkisi

  2019cites this paper
• Functional Changes of Orexinergic Reaction to Psychoactive Substances

  2018cites this paper
• Geriatric Psychopharmacology: A Complex Case of Psychosis Complicated by Neuroleptic Malignant Syndrome (NMS) and Metabolic Syndrome (MetS)

  2018cites this paper
• A comparison of depot and oral atypical antipsychotics in terms of metabolic syndrome markers

  2018cites this paper
• Effects of virtual reality exercise for Korean adults with schizophrenia in a closed ward

  2018cites this paper
• Combination therapy as a potential risk factor for the development of type 2 diabetes in patients with schizophrenia: the GOMAP study

  2018cites this paper
• Long-Term Evolution of Metabolic Status in Patients with Schizophrenia Stably Maintained on Second-Generation Antipsychotics

  2018cites this paper
• The physical health of young people experiencing first‐episode psychosis: Mental health consumers’ experiences

  2018cites this paper
• Six months' course and outcome of metabolic abnormalities in a cohort of patients with schizophrenia in rural India.

  2018cites this paper
• Rediscovery of penicillin of psychiatry: haloperidol decanoate

  2018influential citation
• The Influence of Metabolic Syndrome and Sex on the DNA Methylome in Schizophrenia

  2018cites this paper
• The association between rehabilitation programs and metabolic syndrome in chronic inpatients with schizophrenia.

  2018cites this paper
• Risk of weight gain for specific antipsychotic drugs: a meta-analysis

  2018cites this paper
• Metabolic syndrome in antipsychotic naive African patients with severe mental illness in usual care

  2018influential citation
• Metabolic Syndrome among Schizophrenic Patients: A Comparative Cross-Sectional Study in the Middle Belt of Ghana

  2018cites this paper
• Effects of clozapine on adipokine secretions/productions and lipid droplets in 3T3-L1 adipocytes.

  2017cites this paper
• The Role of Antipsychotic Medications in Metabolic Syndrome Amongst aPredisposed Population: Review of The Saudi Case

  2017cites this paper
• Simulated Effects of Policies to Reduce Diabetes Risk Among Adults With Schizophrenia Receiving Antipsychotics.

  2017cites this paper
• Metabolic syndrome and atypical antipsychotics: Possibility of prediction and control

  2017cites this paper
• The Validity and Reliability Characteristics of the M-BACK Questionnaire to Assess the Barriers, Attitudes, Confidence, and Knowledge of Mental Health Staff Regarding Metabolic Health of Mental Health Service Users

  2017cites this paper
• Prevalence and predictors of metabolic syndrome in schizophrenia patients from Assam

  2017cites this paper
• Metabolic syndrome and atypical antipsychotics: Possibility of prediction and control.

  2017cites this paper
• A comparison of depot and oral atypical antipsychotics in terms of metabolic syndrome markers

  2017cites this paper
• Predictors of rapid high weight gain in schizophrenia: Longitudinal analysis of the French FACE-SZ cohort.

  2017cites this paper
• The physical health and lifestyle of young people at ultra-high risk for psychosis

  2017cites this paper
• Diabetes Mellitus and Acute Hyperglycemia

  2017cites this paper
• Prevalence of obesity and diabetes in patients with schizophrenia

  2017cites this paper
• Crosstalk between insulin and dopamine signaling: A basis for the metabolic effects of antipsychotic drugs.

  2017cites this paper
• The Editorial Assistants – Jordan

  2017cites this paper
• Metabolic syndrome or glucose challenge in first episode of psychosis?

  2017cites this paper
• Psychoses and cardiovascular disease: The heart and mind of the matter

  2016cites this paper
• Current Data on and Clinical Insights into the Treatment of First Episode Nonaffective Psychosis: A Comprehensive Review

  2016cites this paper
• Clozapine modifies the differentiation program of human adipocytes inducing browning

  2016cites this paper
• Would Better Policing of Metabolic Status Help You Avoid Medicolegal Worries

  2016cites this paper
• Prevalence and Predictors of Metabolic Syndrome in People With Schizophrenia in Inpatient Rehabilitation Wards

  2016cites this paper
• Paliperidone Palmitate and Metabolic Syndrome in Patients With Schizophrenia: A 12-Month Observational Prospective Cohort Study

  2016cites this paper
• Factores determinantes del riesgo metabólico en el tratamiento con antipsicóticos atípicos

  2016cites this paper
• Cardiometabolic Risk and Monitoring in Psychiatric Disorders

  2016cites this paper
• Prevalence of Metabolic Syndrome in Patients with Schizophrenia in Korea: A Multicenter Nationwide Cross-Sectional Study

  2016cites this paper
• Prevalence and determinants of metabolic syndrome in patients with schizophrenia: A systematic review and meta-analysis of Indian studies.

  2016cites this paper
• An Overview of Diabetes Management in Schizophrenia Patients: Office Based Strategies for Primary Care Practitioners and Endocrinologists

  2015influential citation
• Diabetes mellitus and severe mental illness: mechanisms and clinical implications

  2015cites this paper
• Metabolic syndrome in acute psychiatric inpatients: clinical correlates Sindrome metabolica in pazienti ricoverati in S.P.D.C.: correlati clinici

  2015cites this paper
• Canadian Guidelines on Pharmacotherapy for Disruptive and Aggressive Behaviour in Children and Adolescents with Attention-Deficit Hyperactivity Disorder, Oppositional Defiant Disorder, or Conduct Disorder

  2015cites this paper
• Schizophrenia, antipsychotic drugs and cardiovascular risk: Descriptive study in primary care

  2015cites this paper